Lesley A Inker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8531770/publications.pdf

Version: 2024-02-01

174 papers	19,017 citations	32410 55 h-index	15253 130 g-index
175 all docs	175 docs citations	175 times ranked	20263 citing authors

#	Article	IF	Citations
1	Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population. Nephrology Dialysis Transplantation, 2023, 38, 119-128.	0.4	21
2	Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrology Dialysis Transplantation, 2022, 37, 1461-1471.	0.4	4
3	A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. American Journal of Kidney Diseases, 2022, 79, 268-288.e1.	2.1	314
4	Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care. CKJ: Clinical Kidney Journal, 2022, 15, 442-451.	1.4	29
5	A metabolomics approach identified toxins associated with uremic symptoms in advanced chronic kidney disease. Kidney International, 2022, 101, 369-378.	2.6	3
6	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	3.0	10
7	National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories. Clinical Chemistry, 2022, 68, 511-520.	1.5	70
8	Letter by Inker et al Regarding Article, â€œPitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failureâ€• Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008983.	1.6	1
9	A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney International, 2022, 101, 607-614.	2.6	22
10	Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization. American Journal of Cardiology, 2022, 165, 124-130.	0.7	6
11	Improved Performance in Measurement of Serum Cystatin C by Laboratories Participating in the College of American Pathologists 2019 CYS Survey. Archives of Pathology and Laboratory Medicine, 2022, 146, 1218-1223.	1.2	10
12	Î²2-Microglobulin and Î²-Trace Protein in Patients Undergoing Bariatric Surgery: Non-GFR Determinants and Panel-estimated GFR Performance. Kidney Medicine, 2022, 4, 100401.	1.0	0
13	Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease. American Journal of Kidney Diseases, 2022, 80, 502-512.e1.	2.1	15
14	Performance of Serum Î²2-Microglobulinâ€“ and Î²-Trace Proteinâ€“Based Panel Markers and 2021 Creatinine- and Cystatin-Based GFR Estimating Equations in Pakistan. Kidney Medicine, 2022, 4, 100444.	1.0	5
15	Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases. Kidney Medicine, 2022, 4, 100442.	1.0	5
16	The authors reply:. Kidney International, 2022, 101, 1088-1089.	2.6	0
17	FC078: Impact of Removing Race from the CKD-EPI Equation: Analysis of 1.6 Million Swedish Adults. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	5
18	FC052: Atrasentan for the Treatment of IGA Nephropathy: Interim Results from the Affinity Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	4

#	Article	IF	Citations
19	FC078: Impact of Removing Race from the CKD-EPI Equation: Analysis of 1.6 Million Swedish Adults. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
20	Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease. New England Journal of Medicine, 2022, 386, 2120-2128.	13.9	58
21	Performance of the 2021 CKD-EPI equations without a race coefficient in a multi-racial population of adults with solid tumors: A prospective cross-sectional study.. Journal of Clinical Oncology, 2022, 40, 12064-12064.	0.8	2
22	Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, .	1.6	4
23	Cystatin C and Muscle Mass in Patients With Heart Failure. Journal of Cardiac Failure, 2021, 27, 48-56.	0.7	10
24	Long-Term Longitudinal Stability of Kidney Filtration Marker Measurements: Implications for Epidemiological Studies and Clinical Care. Clinical Chemistry, 2021, 67, 425-433.	1.5	12
25	Improving Glomerular Filtration Rate Estimationâ€"Across the Age and Diversity Spectrum. Annals of Internal Medicine, 2021, 174, 265-267.	2.0	10
26	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. American Journal of Nephrology, 2021, 52, 180-189.	1.4	31
27	Promoting Equity in Eligibility for Registration on the Kidney Transplantation Waiting List: Looking beyond eGFRcr. Journal of the American Society of Nephrology: JASN, 2021, 32, 523-525.	3.0	4
28	In Search of a Better Equation â€" Performance and Equity in Estimates of Kidney Function. New England Journal of Medicine, 2021, 384, 396-399.	13.9	92
29	Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report from the NKF-ASN Task Force. Journal of the American Society of Nephrology: JASN, 2021, 32, 1305-1317.	3.0	64
30	New GFR-estimating equations for children and young adults in North America and Europe. Kidney International, 2021, 99, 808-811.	2.6	0
31	Performance and Determinants of Serum Creatinine and Cystatin Câ€"Based GFR Estimating Equations in South Asians. Kidney International Reports, 2021, 6, 962-975.	0.4	14
32	A New Panel-Estimated GFR, Including Î²2-Microglobulin and Î²-Trace Protein and Not Including Race, Developed in a Diverse Population. American Journal of Kidney Diseases, 2021, 77, 673-683.e1.	2.1	47
33	In Reply to â€œMultiple-Biomarker Panel Estimated GFR Is Not Optimal or Cost-Effectiveâ€• and â€œComparing Multiple-Biomarker Panels for Estimating GFR With Estimating Equations Without a Coefficient Distinguishing Black Individuals From Persons of Other Groupsâ€• American Journal of Kidney Diseases, 2021, 77, 824.	2.1	1
34	Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report From the NKF-ASN Task Force. American Journal of Kidney Diseases, 2021, 78, 103-115.	2.1	86
35	Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Abnormal Serum Potassium Level. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1094-1096.	2.2	6
36	Removing race from GFR estimates: balancing potential benefits and unintended consequences. Kidney International, 2021, 100, 11-13.	2.6	5

#	Article	IF	Citations
37	Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 340-349.e1.	2.1	28
38	New Creatinine- and Cystatin Câ€“Based Equations to Estimate GFR without Race. New England Journal of Medicine, 2021, 385, 1737-1749.	13.9	1,236
39	A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 2994-3015.	3.0	167
40	Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. American Journal of Kidney Diseases, 2021, 78, 736-749.	2.1	89
41	Measured and estimated glomerular filtration rate: current status and future directions. Nature Reviews Nephrology, 2020, 16, 51-64.	4.1	166
42	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American Journal of Kidney Diseases, 2020, 75, 84-104.	2.1	311
43	â€œShould the definition of CKD be changed to include age-adapted GFR criteria?â€• Kidney International, 2020, 97, 37-40.	2.6	28
44	GFR slope as a surrogate endpoint for CKD progression in clinical trials. Current Opinion in Nephrology and Hypertension, 2020, 29, 581-590.	1.0	8
45	Effect of Loop Diuretics on the Fractional Excretion of Urea in Decompensated Heart Failure. Journal of Cardiac Failure, 2020, 26, 402-409.	0.7	6
46	The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. Journal of the American Society of Nephrology: JASN, 2020, 31, 1847-1858.	3.0	28
47	Estimating Glomerular Filtration Rate in African American Individualsâ€”Reply. JAMA Internal Medicine, 2020, 180, 1549.	2.6	0
48	Performance of Glomerular Filtration Rate Estimating Equations Before and After Bariatric Surgery. Kidney Medicine, 2020, 2, 699-706.e1.	1.0	21
49	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	1.2	4,468
50	The kidney evaluation of living kidney donor candidates: US practices in 2017. American Journal of Transplantation, 2020, 20, 3379-3389.	2.6	29
51	Metabolic, cardiovascular, and substance use evaluation of living kidney donor candidates: US practices in 2017. American Journal of Transplantation, 2020, 20, 3390-3400.	2.6	21
52	Kidney Disease, Race, and GFR Estimation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1203-1212.	2.2	168
53	Bisphosphonate utilization across the spectrum of eGFR. Archives of Osteoporosis, 2020, 15, 69.	1.0	4
54	Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR. Kidney International Reports, 2020, 5, 734-737.	0.4	2

#	Article	IF	Citations
55	GFR in Healthy Aging: an Individual Participant Data Meta-Analysis of Iohexol Clearance in European Population-Based Cohorts. Journal of the American Society of Nephrology: JASN, 2020, 31, 1602-1615.	3.0	68
56	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2020, 97, 1117-1129.	2.6	407
57	Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Internal Medicine, 2020, 180, 718.	2.6	107
58	GFR Estimation Using a Panel of Filtration Markers in Shanghai and Beijing. Kidney Medicine, 2020, 2, 172-180.	1.0	6
59	Estimating total small solute clearance in patients treated with continuous ambulatory peritoneal dialysis without urine and dialysate collection. Peritoneal Dialysis International, 2020, 40, 84-92.	1.1	2
60	Estimation of Glomerular Filtration Rate With vs Without Including Patient Race. JAMA Internal Medicine, 2020, 180, 793.	2.6	64
61	Performance of Indexed and Nonindexed Estimated GFR. American Journal of Kidney Diseases, 2020, 76, 446-449.	2.1	19
62	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. American Journal of Kidney Diseases, 2020, 76, 842-850.	2.1	4
63	Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. Journal of the American Society of Nephrology: JASN, 2019, 30, 1746-1755.	3.0	109
64	Knowing your GFRâ€”when is the number not (exactly) the number?. Kidney International, 2019, 96, 280-282.	2.6	2
65	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. Journal of the American Society of Nephrology: JASN, 2019, 30, 1756-1769.	3.0	71
66	Mixedâ€effects models for slopeâ€based endpoints in clinical trials of chronic kidney disease. Statistics in Medicine, 2019, 38, 4218-4239.	0.8	32
67	Validation of a simple equation for glomerular filtration rate measurement based on plasma iohexol disappearance. CKJ: Clinical Kidney Journal, 2019, 13, 397-401.	1.4	3
68	Novel associations between blood metabolites and kidney function among Bogalusa Heart Study and Multi-Ethnic Study of Atherosclerosis participants. Metabolomics, 2019, 15, 149.	1.4	13
69	Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1581-1589.	2.2	38
70	Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Mayo Clinic Proceedings, 2019, 94, 2220-2229.	1.4	39
71	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology: JASN, 2019, 30, 1735-1745.	3.0	163
72	Change in albuminuria as a surrogate endpoint in chronic kidney disease â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2019, 7, 336-337.	5.5	11

#	Article	IF	Citations
73	Strengths and limitations of estimated and measured GFR. Nature Reviews Nephrology, 2019, 15, 784-784.	4.1	38
74	Development and Validation of Residual Kidney Function Estimating Equations in Dialysis Patients. Kidney Medicine, 2019, 1, 104-114.	1.0	9
75	Serum and Urine Albumin and Response to Loop Diuretics in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 712-718.	2.2	22
76	Improving glomerular filtration rate estimation. Kidney International, 2019, 95, 1017-1019.	2.6	5
77	The Serum Metabolome Identifies Biomarkers of Dietary Acid Load in 2 Studies of Adults with Chronic Kidney Disease. Journal of Nutrition, 2019, 149, 578-585.	1.3	14
78	Serum Metabolomic Alterations Associated with Proteinuria in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 342-353.	2.2	34
79	Serum metabolites associated with dietary protein intake: results from the Modification of Diet in Renal Disease (MDRD) randomized clinical trial. American Journal of Clinical Nutrition, 2019, 109, 517-525.	2.2	21
80	Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS. Clinical Chemistry, 2019, 65, 406-418.	1.5	16
81	Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis. Mayo Clinic Proceedings, 2019, 94, 17-26.	1.4	18
82	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	5.5	199
83	Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 469-481.	2.2	128
84	Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study. Nephrology Dialysis Transplantation, 2019, 34, 825-833.	0.4	37
85	A Roadmap for Estimated Glomerular Filtration Rate: Where Have We Been, Where Are We Now, and Where Do We Need to Go?. Advances in Chronic Kidney Disease, 2018, 25, 4-6.	0.6	0
86	Assessment of Glomerular Filtration Rate and End-Stage Kidney Disease Risk in Living Kidney Donor Candidates: A Paradigm for Evaluation, Selection, and Counseling. Advances in Chronic Kidney Disease, 2018, 25, 21-30.	0.6	12
87	Estimated Glomerular Filtration Rate From a Panel of Filtration Markersâ€"Hope for Increased Accuracy Beyond Measured Glomerular Filtration Rate?. Advances in Chronic Kidney Disease, 2018, 25, 67-75.	0.6	52
88	Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. American Journal of Nephrology, 2018, 47, 40-47.	1.4	123
89	In Reply to â€˜How Valid Are GFR Estimation Results From the CKD-EPI Databases?â€™. American Journal of Kidney Diseases, 2018, 71, 447.	2.1	0
90	Improving Carboplatin Dosing Based on EstimatedÂGFR. American Journal of Kidney Diseases, 2018, 71, 163-165.	2.1	16

#	Article	IF	Citations
91	Performance of glomerular filtration rate estimating equations in a community-based sample of Blacks and Whites: the multiethnic study of atherosclerosis. Nephrology Dialysis Transplantation, 2018, 33, 417-425.	0.4	36
92	Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Translational Research, 2018, 195, 25-47.	2.2	43
93	1547. BK Virus Reactivation in Solitary Heart Transplant Recipients: Prevalence and Relationship to Kidney Dysfunction. Open Forum Infectious Diseases, 2018, 5, S480-S480.	0.4	0
94	Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1886-1888.	2.2	21
95	Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging. American Journal of Kidney Diseases, 2018, 72, 771-773.	2.1	5
96	SP121A PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME. Nephrology Dialysis Transplantation, 2018, 33, i384-i385.	0.4	5
97	New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines. Transplant Infectious Disease, 2018, 20, e12985.	0.7	11
98	FP110A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2018, 33, i14-i14.	0.4	2
99	FP806INITIAL RESULTS FROM A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2018, 33, i635-i635.	0.4	1
100	Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression. Journal of the American Society of Nephrology: JASN, 2018, 29, 1939-1947.	3.0	13
101	Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney International, 2018, 94, 381-389.	2.6	42
102	Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1013-1021.	2.2	23
103	Effects of Body Size and Composition on Sex Differences in Measured GFR in a USÂCommunity-Based Older Cohort (MESA-Kidney). American Journal of Kidney Diseases, 2018, 72, 767-770.	2.1	3
104	How best to estimate glomerular filtration rate? Novel filtration markers and their application. Current Opinion in Nephrology and Hypertension, 2018, 27, 398-405.	1.0	18
105	Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1144-1152.	2.2	50
106	Biological Variability of Estimated GFR and Albuminuria in CKD. American Journal of Kidney Diseases, 2018, 72, 538-546.	2.1	62
107	Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function. JAMA Internal Medicine, 2018, 178, 903.	2.6	126
108	FO022BARDOXOLONE METHYL PREVENTS EGFR DECLINE IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. Nephrology Dialysis Transplantation, 2018, 33, i10-i10.	0.4	2

#	Article	IF	Citations
109	Aortic stiffness and change in glomerular filtration rate and albuminuria in older people. Nephrology Dialysis Transplantation, 2017, 32, gfw050.	0.4	12
110	Strategies for Assessing GFR and Albuminuria in the Living Kidney Donor Evaluation. Current Transplantation Reports, 2017, 4, 13-23.	0.9	9
111	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in the Elderly: AGES-Kidney and MESA-Kidney. American Journal of Kidney Diseases, 2017, 70, 406-414.	2.1	50
112	Comparing Newer GFR Estimating Equations Using Creatinine and Cystatin C to the CKD-EPI Equations in Adults. American Journal of Kidney Diseases, 2017, 70, 587-589.	2.1	30
113	Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2017, 70, 337-346.	2.1	52
114	GFR Evaluation in Living Kidney Donor Candidates. Journal of the American Society of Nephrology: JASN, 2017, 28, 1062-1071.	3.0	39
115	Metabolomic Alterations Associated with Cause of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1787-1794.	2.2	54
116	Hyperkalemia After Initiating Reninâ€“Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. Journal of the American Heart Association, 2017, 6, .	1.6	123
117	In Reply to â€˜Newer GFR Estimating Equations Require Validation in Different Populationsâ€™. American Journal of Kidney Diseases, 2017, 70, 586-587.	2.1	2
118	Risk of ESRD and Mortality Associated With Change in Filtration Markers. American Journal of Kidney Diseases, 2017, 70, 551-560.	2.1	20
119	A tripartite complex of suPAR, APOL1 risk variants and Î±vÎ²3 integrin on podocytes mediates chronic kidney disease. Nature Medicine, 2017, 23, 945-953.	15.2	176
120	Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 69-78.	2.2	24
121	A Dynamic Predictive Model for Progression of CKD. American Journal of Kidney Diseases, 2017, 69, 514-520.	2.1	78
122	Novel Filtration Markers for GFR Estimation. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2017, 28, 277-288.	0.7	10
123	In Reply. Archives of Pathology and Laboratory Medicine, 2016, 140, 207-208.	1.2	2
124	O1â€02â€02: Decline in Kidney Function and Subclinical Brain Pathologies. Alzheimer's and Dementia, 2016, 12, P173.	0.4	0
125	Serum Î²-Trace Protein and Î²2-Microglobulin as Predictors of ESRD, Mortality, and Cardiovascular Disease in Adults With CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2016, 68, 68-76.	2.1	61
126	Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 392-401.	2.1	85

#	Article	IF	Citations
127	Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. Hypertension, 2016, 67, 1181-1188.	1.3	99
128	Non-GFR Determinants of Low-Molecular-Weight Serum ProteinÂFiltration Markers in CKD. American Journal of Kidney Diseases, 2016, 68, 892-900.	2.1	70
129	Serum Potassium, Mortality, and Kidney Outcomes in the Atherosclerosis Risk in Communities Study. Mayo Clinic Proceedings, 2016, 91, 1403-1412.	1.4	45
130	Effects of Race and Sex on Measured GFR: The Multi-Ethnic Study of Atherosclerosis. American Journal of Kidney Diseases, 2016, 68, 743-751.	2.1	40
131	Managing Chronic Kidney Disease in Older Peopleâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 315, 307.	3.8	4
132	Past Decline Versus Current eGFR and Subsequent Mortality Risk. Journal of the American Society of Nephrology: JASN, 2016, 27, 2456-2466.	3.0	40
133	Estimating residual kidney function in dialysis patients without urine collection. Kidney International, 2016, 89, 1099-1110.	2.6	71
134	GFR as the â€œGold Standardâ€: Estimated, Measured, and True. American Journal of Kidney Diseases, 2016, 67, 9-12.	2.1	78
135	Cerebrovascular Damage Mediates Relations Between Aortic Stiffness and Memory. Hypertension, 2016, 67, 176-182.	1.3	107
136	Prevalence and complications of chronic kidney disease in a representative elderly population in Iceland. Nephrology Dialysis Transplantation, 2016, 31, 439-447.	0.4	17
137	Biomarkers of Vitamin D Status and Risk of ESRD. American Journal of Kidney Diseases, 2016, 67, 235-242.	2.1	30
138	GFR Estimation Using Î²-Trace Protein and Î²2-Microglobulin inÂCKD. American Journal of Kidney Diseases, 2016, 67, 40-48.	2.1	121
139	A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. Journal of the American Society of Nephrology: JASN, 2016, 27, 1175-1188.	3.0	159
140	Filtration Markers as Predictors of ESRD and Mortality in Southwestern American Indians With Type 2 Diabetes. American Journal of Kidney Diseases, 2015, 66, 75-83.	2.1	43
141	Chronic Kidney Disease in Older People. JAMA - Journal of the American Medical Association, 2015, 314, 557.	3.8	82
142	Comparing GFR Estimating Equations Using Cystatin C and Creatinine in Elderly Individuals. Journal of the American Society of Nephrology: JASN, 2015, 26, 1982-1989.	3.0	132
143	Glomerular Filtration Rate and Albuminuria for Detection and Staging of Acute and Chronic Kidney Disease in Adults. JAMA - Journal of the American Medical Association, 2015, 313, 837.	3.8	431
144	Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 941-948.	2.2	16

#	Article	IF	Citations
145	BK Virus Nephropathy in Heart Transplant Recipients. American Journal of Kidney Diseases, 2015, 65, 949-955.	2.1	16
146	Cross-Disciplinary Biomarkers Research. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 894-902.	2.2	24
147	Serum Fibroblast Growth Factor-23 Is Associated with Incident Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 192-200.	3.0	56
148	Midlife Blood Pressure and Late-Life GFR and Albuminuria: An Elderly General Population Cohort. American Journal of Kidney Diseases, 2015, 66, 240-248.	2.1	28
149	Plasma Iohexol Clearance for Assessing Residual Kidney Function in Dialysis Patients. American Journal of Kidney Diseases, 2015, 66, 728-730.	2.1	13
150	Segmental Kidney Volumes Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Their Association With CKD in Older People. American Journal of Kidney Diseases, 2015, 65, 41-48.	2.1	23
151	Mediation Analysis of Aortic Stiffness and Renal Microvascular Function. Journal of the American Society of Nephrology: JASN, 2015, 26, 1181-1187.	3.0	97
152	Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. Nephrology Dialysis Transplantation, 2014, 29, 1195-1203.	0.4	76
153	Utility and Validity of Estimated GFRâ€“Based Surrogate Time-to-Event End Points in CKD: A Simulation Study. American Journal of Kidney Diseases, 2014, 64, 867-879.	2.1	59
154	GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials. American Journal of Kidney Diseases, 2014, 64, 848-859.	2.1	109
155	GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials. American Journal of Kidney Diseases, 2014, 64, 860-866.	2.1	108
156	GFR Decline as an End Point for Clinical Trials in CKD: AÂScientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases, 2014, 64, 821-835.	2.1	430
157	Albuminuria: Time to Focus on Accuracy. American Journal of Kidney Diseases, 2014, 63, 378-381.	2.1	16
158	Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis. American Journal of Kidney Diseases, 2014, 64, 74-85.	2.1	104
159	Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population. American Journal of Kidney Diseases, 2014, 63, 753-760.	2.1	13
160	Estimation of GFR in South Asians: A Study From the General Population in Pakistan. American Journal of Kidney Diseases, 2014, 63, 49-58.	2.1	69
161	In Reply to â€˜Creatinine-Based GFR Estimating Equations in Kidney Transplant Recipientsâ€™ and â€˜Assessing Kidney Function in Transplant Recipients: Time to Work Together and Address theÂMost Relevant Questionsâ€™. American Journal of Kidney Diseases, 2014, 64, 819.	2.1	6
162	Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Nonâ€“Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). American Journal of Kidney Diseases, 2014, 63, 244-250.	2.1	55

#	Article	IF	Citations
163	Cystatin C for Glomerular Filtration Rate Estimation: Coming of Age. Clinical Chemistry, 2014, 60, 916-919.	1.5	28
164	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. American Journal of Kidney Diseases, 2014, 63, 713-735.	2.1	1,249
165	Performance of Creatinine-Based GFR Estimating Equations inÂSolid-Organ Transplant Recipients. American Journal of Kidney Diseases, 2014, 63, 1007-1018.	2.1	103
166	GFR Estimation: From Physiology to Public Health. American Journal of Kidney Diseases, 2014, 63, 820-834.	2.1	427
167	Calibration of Cystatin C in the National Health and Nutrition Examination Surveys (NHANES). American Journal of Kidney Diseases, 2013, 61, 353-354.	2.1	21
168	Pro: Estimating GFR using the chronic kidney disease epidemiology collaboration (CKD-EPI) 2009 creatinine equation: the time for change is now. Nephrology Dialysis Transplantation, 2013, 28, 1390-1396.	0.4	29
169	Performance of Creatinine and Cystatin C GFR Estimating Equations in an HIV-Positive Population on Antiretrovirals. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 302-309.	0.9	78
170	Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine, 2012, 367, 20-29.	13.9	3,072
171	Comparison of Concurrent Complications of CKD by 2 Risk Categorization Systems. American Journal of Kidney Diseases, 2012, 59, 372-381.	2.1	14
172	Cystatin C as a marker of glomerular filtration rate. Current Opinion in Nephrology and Hypertension, 2011, 20, 631-639.	1.0	61
173	Estimated GFR, Albuminuria, and Complications of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2011, 22, 2322-2331.	3.0	88
174	Weight changes following antidiabetic mediation use: realâ€world evidence from health system data. Obesity Science and Practice, 0, , .	1.0	0